JAMA — Bommareddy K, Hamade H, Lopez-Olivo MA, et al. | February 11, 2022
Treatment with spironolactone does not seem to be linked with a meaningful increase in risk of cancer occurrence.
In this systematic review and meta-analysis of 7 observational studies, the pooled occurrence of malignancies, in particular breast and prostate cancers, was determined among those who ever used spironolactone.
As per observations, spironolactone use was not linked with statistically significant elevated risks of breast or other solid organ cancers.
It was also found to be linked with a reduced risk of prostate cancer.
Read the full article on JAMA